Symposium 6

February 4, 2013 Pre-symposium workshop
08.00 hrs onwards Registration and Morning Coffee
08.45 hrs

Chairpersons Opening Remarks

09.00 – 10.00 hrs

Potential of Cellular analysis in Drug Discovery and Early Toxicology studies– The GE Healthcare Integrated Platform
GE Healthcare
10.00 – 11.00 hrs
Semiconductor sequencing- a boon to translational Research
Life Technologies
11.00 – 11.30 hrs Tea Break
11.30 – 12.30 hrs Paper Trails to Electronic Data Management
PerkinElmer (Informatics)
12.30 – 13.30 hrs High Resolution Mass Spectrometry for Pharmaceutical Applications
AB SciEx
13.30 – 15.00 hrs
Lunch, Poster & Networking session
15.00 – 16.00 hrs
Innovative strategy to locate, screen and identify new chemical entities using STN and SciFinder databases
Sci-Edge Information

16.00 – 17.00 hrs

Drug transporters in drug discovery: methods and regulatory considerations
Solvo Biotechnology, Hungary

17.00 – 18.30 hrs

Application of High Resolution Mass Spectrometry and Ion Mobility Separations for Systems Biology Applications

  • Introducing the latest Waters MS technology platforms
  • Protein profiling and biomarker validation
  • Protein characterization
  • Metabonomics and structural elucidation
  • Lipidomics and lipid characterization
  • Imaging by Mass Spectrometry

Waters Ltd.


February 5, 2013
08.30 – 09.00 hrs Morning Coffee
09.00 – 09.30 hrs Inauguration
09.30 –
10.30 hrs
Peter Schultz
Keynote Address
A Chemist’s Foray into Translational Research

Dr. Peter Schultz
Director, Calibr Institute, Professor of Chemistry, The Scripps Research Institute, USA
Founder of Affymax Research Institute, Syrrx, Kalypsys, Phenomix, Symyx Therapeutics, Ilypsa, Ambrx, Ardelyx, and Wildcat Technologies
10.30 – 11.00 hrs Tea Break
11.00 –
11.45 hrs
Pierre Riviere
Keynote Address
Peptide Therapeutics and the Quest For Differentiated Medicines

Dr. Pierre Rivière
Sr. Vice President, Global R&D, Pfizer, USA
11.45 –
12.30 hrs
Frontloading Toxicity Detection in order to Lower Costs and Attrition

Dr. Bruce Car
Vice President, Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Company, USA
12.30 –
13.15 hrs
Pierre Riviere
Western biotech & Emerging Market pharma alliances: explosive value creation or hype?

Dr. Stephen Yoder
CEO, Pieris AG, Germany
13.15 – 15.00 hrs Lunch, Poster & Networking session
15.00 –
15.45 hrs
Pierre Riviere
Playing the numbers game in small-molecule lead discovery

Dr. Alex Haahr Gouliaev
CEO, Nuevolution, Denmark
15.45 –
16.30 hrs
Pierre Riviere
“Studies Towards Development Of Pcsk9 Inhibitors For Regulating LDL-R and Cholesterol”

Dr. Ajoy Basak
Department of Biochemistry, Microbiology & Immunology, Faculty of Medicine and Interdisciplinary School of Health Sciences, University of Ottawa, Canada
16.30 – 17.00 hrs Tea Break
17.00 –
17.45 hrs
FGF21-Adnectin-Pharmacokinetic Enhancer: A modified FGF21 protein with uniquely extended Pharmacokinetic Profile for the Treatment of Metabolic Diseases.

Dr. Ranjan Mukherjee
Department of Metabolic Diseases, Bristol-Myers Squibb Company, USA
17.45 –
18.30 hrs

Inflammation, Mitochondrial Dysfunction and Insulin Resistance- implications for antidiabetic drug discovery.

Dr. Satinath Mukhopadhyay
Professor, Department of Endocrinology and Metabolism, Institute of Postgraduate Medical Education & Research, Kolkata, india.

18.30 –
19.15 hrs

Panel discussion

  • Dr. Peter Schultz
  • Dr. Pierre Rivière
  • Dr. Bruce Car
  • Dr. Alex Haahr Gouliaev
  • Dr. Stephen Yoder
  • Dr. Ranjan Mukherjee
  • Dr. Satinath Mukhopadhyay
  • Dr. Ajoy Basak
  • Dr. Kapil Dhingra


February 6, 2013
08.00 – 08.30 hrs Morning Coffee

08.30 –
09.15 hrs

 Pierre Riviere

Keynote Address
Oncology 2013: Recent advances in personalized therapy of cancer

Dr. Kapil Dhingra
Retired Vice President, Head, Oncology Disease Biology Leadership Team, Roche, Director, KAPital Consulting LLC, USA

09.15 –
10.00 hrs

 Pierre Riviere

Keynote Address
Combined Targeted Therapy in Sarcomas-Pathways to Success?

Dr. Lee Helman
Head & Senior Investigator, Molecular Oncology Section, National Cancer Institute, USA

10.00 – 10.30 hrs

Tea Break

10.30 –
11.15 hrs

 Pierre Riviere

Personalized Therapy in Oncology - what they don’t tell you

Dr. Purvish M. Parikh
Managing Director, AmeriCares, India

11.15 –
12.00 hrs
Novalties on BCR/ABL

Dr Martin Ruthardt
Head, Laboratory of Tumor Stem Cell Biology, Univeristy of Frankfurt, Germany

12.00 –
12.45 hrs

 Pierre Riviere

Disease, Process and Partners: Challenges of Biomarker and Diagnostic Development in Oncology

Dr Anjan Thakurta
Sr. Director, Translational Development, Celgene, USA

12.45 – 13.30 hrs Lunch, Poster & Networking session

13.30 –
14.00 hrs


Locks, Clocks and Peacocks

Dr. Hiren Shah
Ahmedabad, India

14.00 –
14.45 hrs
Keynote Address
Adjuvants to Enable Next Generation Vaccines

Dr. Steven G. Reed
Founder, President, & Chief Scientific Officer, Infectious Disease Research Institute, USA

14.45 –
15.30 hrs

Pierre Riviere

TLR7 in oncology and as an adjuvant

Dr. Johanna Holldack
Chief Executive Officer, Telormedix SA, Switzerland

15.30 – 16.00 hrs Tea Break
16.00 –
16.45 hrs
Pierre Riviere

Predicting responses to vaccination with systems biology: What have we learned so far ?

Dr. Jan ter Meulen
Executive Director, Vaccine Research, Merck Research Laboratories, USA

16.45 –
17.30 hrs
Panel Discussion
  • Dr. Kapil Dhingra
  • Dr. Lee Helman
  • Dr. Purvish M. Parikh
  • Dr Anjan Thakurta
  • Dr. Johanna Holldack
  • Dr. Steven G. Reed
  • Dr. Jan ter Meulen

17.30 – 18.00 hrs

Best Poster Award Lecture 1 & 2

18.00 hrs

Vote of Thanks


Home Contact Us